Catalent, Inc. CTLT
Set alert
At close · Dec 17
52-week range unavailable
- Open
- 63.49
- Prev close
- 63.48
- Mkt cap
- 11.52B
- Vol
- 13.67M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 63.44
- High
- 63.50
- Earnings
- Nov 5, 2024
News
2 weeks ago businesswire.com
Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and…
2 months ago reuters.com
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking FDA approval for a rare neuromuscular disease drug.
3 months ago globenewswire.com
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.
4 months ago businesswire.com
Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services
TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent's network.
6 months ago businesswire.com
Cartherics and Catalent Expand Commercial License Agreement
MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian…
7 months ago businesswire.com
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.
9 months ago businesswire.com
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies.
12 months ago globenewswire.com
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies…
1 year ago businesswire.com
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that…
1 year ago proactiveinvestors.com
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability…
-
1 year ago proactiveinvestors.com
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces its...
1 year ago proactiveinvestors.com
Lisata Therapeutics inks global product license deal with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a global product license agreement with Catalent Inc, which would allow Catalent to incorporate Lisata's certepetide into…
1 year ago benzinga.com
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock's SRRK apitegromab Biologics License Application (BLA) for spinal muscular atrophy…
1 year ago investors.com
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant.
1 year ago globenewswire.com
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Science 37 and Catalent announce a strategic partnership enabling direct-to-patient investigational medicinal product (IMP) delivery for clinical research.
1 year ago globenewswire.com
Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More
Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Key industry drivers include cost advantages in China, 100% FDI in India,…
1 year ago businesswire.com
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director.
1 year ago proactiveinvestors.com
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI
Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors…
1 year ago proactiveinvestors.com
Lisata Therapeutics signs research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's…
1 year ago globenewswire.com
Lisata Therapeutics Announces Research License with Catalent
BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies…
-
2 years ago benzinga.com
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.
-
2 years ago benzinga.com
Earnings Scheduled For February 9, 2024
Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.
-
2 years ago benzinga.com
Earnings Scheduled For November 15, 2023
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is likely to report earnings for its third quarter. • Movano (NASDAQ:MOVE) is projected to report earnings for its third…
-
3 years ago benzinga.com
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for…
-
3 years ago benzinga.com
Earnings Scheduled For August 29, 2023
Companies Reporting Before The Bell • VEON (NASDAQ:VEON) is estimated to report earnings for its second quarter.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 120 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For May 15, 2023
Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 199 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 164 companies hit new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 61 companies hit new 52-week lows.
-
3 years ago benzinga.com
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
-
3 years ago benzinga.com
US Stocks Edge Lower; Tyson Foods Posts Q2 Loss
U.S. stocks traded slightly lower this morning, with the Dow Jones dropping around 40 points on Monday. Following the market opening Monday, the Dow traded down 0.12% to 33,635.06 while the NASDAQ…
-
3 years ago benzinga.com
Earnings Scheduled For February 7, 2023
Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 85 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 96 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday, 125 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 446 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday saw 177 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 200 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 402 companies made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 340 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 529 companies set new 52-week lows.
-
4 years ago benzinga.com
80 Biggest Movers From Yesterday
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
-
4 years ago benzinga.com
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.